- $3.14bn
- $3.06bn
- $125.81m
- 24
- 10
- 43
- 14
Annual income statement for HeartFlow, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 87.2 | 126 |
| Cost of Revenue | ||
| Gross Profit | 58.1 | 94.4 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 160 | 187 |
| Operating Profit | -72.9 | -61.2 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -95.1 | -96.4 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -95.7 | -96.4 |
| Net Income Before Extraordinary Items | ||
| Net Income | -95.7 | -96.4 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -124 | -96.4 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.53 | -1.2 |